Don't Count Out Covid-19 Monoclonal Antibody Treatments, Analyst Says. - Barron's
The news early this month that Merck‘s oral Covid-19 antiviral had cut hospitalizations in half in a trial kneecapped the stocks of other biopharma firms that sell monoclonal antibody treatments for the disease.Those monoclonal antibodies, while effective, are generally administered via infusion, which makes them far less convenient than an oral pill.Investors seemed to think that Merck’s (ticker: MRK) pill, called molnupiravir—and other pills under development from Pfizer (PFE) and Atea Pharmaceuticals (AVIR)—would wipe...